Toll Free: (888) 496-4400
Main Office: (801) 264-4444

Clinical Research

For over three decades Rocky Mountain Retina Consultants has been at the forefront of clinical research in the western United States. This allows us to bring the newest treatment options to our patients. We are able to tailor treatment regimens that are not available at other retinal surgery practices. This equates to more progressive care for our patients and physicians and staff who are focused on continually working on improving the care our patients receive.

Participate in Clinical Research

If you are interested in learning more about any of our research studies, or being considered a candidate, please provide your email address below. You can also call (801) 264-4444 and ask to speak with one of our Study Coordinators.

Please enter your email address

Currently Enrolling Studies

  • Please contact our office for information regarding studies for which we are enrolling.

Studies For Which Enrollment Has Been Completed

  • AERPIO
    • AKB-9778-CI-2003 - Assess the safety and efficacy of daily subcutaneous AKB-9778 as monotherapy or adjunctive to ranibizumab, in patients with Diabetic Macular Edema
  • ALCON
    • HAWK - Comparing the efficacy and safety of RTH258 versus Aflibercept in subjects with neovascular age-related macular degeneration.
  • ALLERGAN
    • 206207-012 - Dexamethasone Posterior Segment Drug Delivery System with Diffuse Diabetic Macular Edema - Phase III
    • 206207-016 - Dexamethasone Posterior Segment Drug Delivery System with Choroidal Neovascularization Secondary to Age-Related Macular Degeneration - Phase II
    • 206207-018 - Dexamethasone Posterior Segment Drug Delivery System post Vitrectomy with Diabetic Macular Edema - Open Label
    • 190342-031 - Brimonidine Tartrate Posterior Segment Drug Delivery System with Rhegmatogenous Macular-Off Retina Detachment - Phase II
    • 190342-033D - Brimonidine Tartrate Posterior Segment Drug Delivery System with Rhegmatogenous Macular-Off Retina Detachment - Open Label
    • 190342-036D - Pharmacokinetics of Brimonidine Following Intravitreal Administration of the Brimonidine Tartrate Posterior Segment Drug Delivery System in Subjects Undergoing Pars Plana Vitrectomy - Phase I/II
    • 150998 (REACH) - Intravitreal administration of a single dose of AGN-150998 into patients with exudative Age-Related Macular Degeneration
    • AGN 150998-004 - Evaluation of Abicipar Pegol (AGN-150998) in patient with decreased vision due to diabetic macular edema.
  • CIBA VISION/Novartis/QLT
    • BPD OCR 005 CIBA - Photodynamic Therapy Ind. Study for Macular Degeneration (VAM Study) - Phase IV
  • EMMES
    • SCORE - Standard Care versus Corticosteroid for Retinal Vein Occlusion (SCORE) - Phase III
  • DRCR
    • DRCR protocol A - A Pilot Study of Laser Photocoagulation for Diabetic Macular Edema - Phase II
    • DRCR protocol B - Intravitreal Triamcinolone and Laser Photocoagulation for Diabetic Macular Edema - Phase III
    • DRCR protocol D - Peribulbar Triamcinolone for Diabetic Macular Edema - Phase II
    • DRCR protocol E - Evaluation of Vitrectomy for Diabetic Macular Edema - Phase II
  • GENENTECH
    • FVF2598g - Ranibizumab (Lucentis) in minimally Classic or Occult AMD Study (Marina) - Phase III
    • FVF2587g - Ranibizumab (Lucentis) in Predominantly Classic AMD Study (Anchor) - Phase III
    • FVF3192g - Ranibizumab (Lucentis) with and without Classic CNV in Age-Related Macular Degeneration (Pier) - Phase IIIb
    • FVF3426g Cohort 1 - Ranibizumab (Lucentis) with Subfoveal Choroidal Neovascularization in Age-Related Macular Degeneration (Horizon) - Phase III Open Label
    • FVF3689g - Ranibizumab (Lucentis) with Subfoveal Choroidal Neovascularization in Age-Related Macular Degeneration (Sailor) - Phase IIIb
    • FVF3426g Cohort 2 - Ranibizumab (Lucentis) with Retinal Vein Occlusion (Horizon II) - Open-Label
    • FVF4166g - Ranibizumab (Lucentis) with Macular Edema Secondary to Central Retinal Vein Occlusion (Cruise) - Phase III
    • FVF4165g - Ranibizumab (Lucentis) with Macular Edema Secondary to Branch Retinal Vein Occlusion (Bravo) - Phase III
    • FVF4579g - Ranibizumab (Lucentis) with Subfoveal Neovascular Age-Related Macular Degeneration (Harbor) - Phase III Dose Comparison
    • B1261009 - Compare the efficacy and safety of a Chemokine CCR2/5 receptor antagonist (PF-04634817) with that of ranibizumab in adult subjects with diabetic macular edema.
  • GLAXOSMITHKLINE
    • MD7110852 - Pazopanib Eye Drops versus Ranibizumab Intravitreal Injections with Neovascular Age-Related Macular Degeneration - Phase IIb
  • LPATH
    • LT1009-Oph-003 (NEXUS) - iSONEP as either monotherapy or adjunctive therapy to Lucentis or Avastin versus Lucentis or Avastin alone for the treatment of subjects with Choroidal Neovascularization secondary to Age-Related Macular Degeneration.
  • LILLY
    • B7A-MC-MBBM - Protein Kinase C Inhibitor - Diabetic Retinopathy Study (MBBM) - Phase II/III
    • B7A-MC-MBBK - Protein Kinase C Inhibitor - Diabetic Macular Edema (MBBK) - Phase III
    • B7A-MC-MBCM - Protein Kinase C Inhibitor - Diabetic Retinopathy Study #2 (MBCM) - Phase III
    • B7A-MC-MBDL - Protein Kinase C Inhibitor - Diabetic Macular Edema (MBDL) - Phase III
    • B7A-MC-MBDV - Protein Kinase C Inhibitor - Diabetic Retinopathy Study (MBDV) - Phase III
  • MacuCLEAR
    • MC1101-003 - Establish the efficacy and safety of MC-1101 in patients with non-exudative age-related macular degeneration
    • MC1101-004 - Dose comparison study to evaluate the safety and tolerability of MC-1101 in subjects with early to intermediate non-exudative age-related macular degeneration.
  • MACUSIGHT
    • DR-002 - Sirolimus for Diabetic Macular Edema (Diamond) - Phase II
    • AMD-003 - Sirolimus for Age-Related Macular Degeneration (Emerald) - Phase II
  • NEOVISTA
    • NVI-144-06 - Epi-Rad90 Ophthalmic System for Subfoveal Choroidal Neovascularization with AMD (Cabernet) - Pivotal
  • OPHTHOTECH
    • OPH1001 - Intravenous Injections of E10030 (Anti-PDGF Pegylated Aptamer) Given in Combination with Lucentis® for Neovascular Age-Related Macular Degeneration - Phase II
    • OPH3000 - Volociximab with Neovascular Age-Related Macular Regeneration (OPH 3000) - Phase I
    • FOVISTA
    • OPH1003 - Fovista administered in combination with Lucentis compared to Lucentis monotherapy in subjects with subfoveal neovascular age-related macular degeneration.
    • OPH1004 - Establish the safety and efficacy of intravitreous administration of Fovista administered in combination with either Avastin or Eylea compared to Avastin or Eylea monotherapy in subjects with subfoveal neovascular age-related macular degeneration.
  • OPKO
    • ACU301 - Bevasiranib Sodium with Exudative Age-Related Macular Degeneration (Cobalt) - Phase III
  • (OSI) EYETECH
    • EOP1023 - Pegaptanib Sodium (Macugen) in Subfoveal Neovascular Age-Related Macular Degeneration (LEVEL) - Phase III
  • PIVOT
    • PIVOT - Evaluate myVisionTrack home vision testing in patient with diabetic macular edema or neovascular age-related macular degeneration currently receiving intravitreal Lucentis therapy.
  • REGENERON
    • VGFT-OD-0508 - VEGF Trap with Neovascular Age-Related Macular Degeneration (0508) - Phase II
    • VGFT-OD-0702 - VEGF Trap with Neovascular Age-Related Macular Degeneration (0702) - Open Label
    • VGFT-OD-0605 - VEGF Trap with Neovascular Age-Related Macular Degeneration (0605) - Phase III
    • VGFT-OD-0706 - VEGF Trap with Diabetic Macular Edema (0706) - Phase II
    • VGFT-OD-0910 - VEGF Trap with Neovascular Age-Related Macular Degeneration (0910) - Open Label Phase III
    • VGFT-OD-1009 - Intravitreal administration of VEGF Trap-Eye in patients with Diabetic Macular Edema (DME VISTA) 2011 to present - Phase III
    • RANGE VGFT-0D-1319 - Treat and extend therapy using intravitreal aflibercept for previously treated patients exiting wet age-related macular degeneration extension study (0910) - Phase II
    • R2176-3-AMD-1417 - Multiple-dose regimen-ranging study of the efficacy and safety of intravitreal REGN2176-3 in patient with neovascular age-related macular degeneration.
  • ROCKY MOUNTAIN RETINA CONSULTANTS
    Investigator Sponsored Trial
    • FVF3799s - Ranibizumab (Lucentis) in Diabetic Macular Edema - Phase II
  • VALEANT
    • EOP 1024 (Macugen) - A Phase IV, open label, multi-center study to assess the effect of intravitreal injections of Macugen (pegaptanib sodium injection) administered every 6 weeks for 48 weeks on the corneal endothelium.